Axxam SpA and leadXpro AG announce today a collaboration for the discovery of novel small molecule lead compounds for a newly discovered GPCR involved in inflammatory processes.
In the collaboration, Axxam and leadXpro will combine their expertise in assay development, high throughput screening, membrane protein generation, structure determination and application of biophysical methods to investigate the interaction of small molecule ligands with challenging membrane protein drug targets to facilitate the discovery and optimization of novel lead molecules.
Clicca qui per leggere il comunicato stampa
